Investigational drug · Phase 2
NV-5138
Also called: SPN820
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Treatment Resistant Depression.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "NV-5138"
First trial start
2022
Jan 18, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NV-5138", any sponsor or status.
Conditions studied
As listed on its trial records.
- Treatment Resistant Depression
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "NV-5138" as an intervention, largest first.
- Phase 2 Study of NV-5138 in Adults With Treatment Resistant DepressionPivotal-lookingCompleted
Navitor Pharmaceuticals, Inc.Industry
NCT05066672 · 250 participants · Start Jan 18, 2022 · Primary completion Jan 21, 2025
Drug: NV-5138; matched placebo · For: Treatment Resistant Depression
Sites: Bellevue, Washington
Navitor Pharmaceuticals, Inc.Industry
NCT03606395 · 80 participants · Start Jun 6, 2018 · Primary completion Jun 9, 2019
Drug: NV-5138; Placebos · For: Treatment Resistant Depression
Sites: Birmingham, Alabama; Long Beach, California; San Diego, California · 9 sites in all
Navitor Pharmaceuticals, Inc.Industry
NCT06235905 · 40 participants · Start Feb 15, 2024 · Primary completion Aug 18, 2024
Drug: NV-5138 · For: Major Depressive Disorder
Sites: Temecula, California
Supernus Pharmaceuticals, Inc.Industry
NCT05384977 · 6 participants · Start Nov 11, 2021 · Primary completion Dec 9, 2021
Drug: [14C]-NV-5138 · For: Healthy Volunteers
Sites: Ruddington, United Kingdom
Navitor Pharmaceuticals, Inc.Industry
NCT05152680 · 6 participants · Start Nov 11, 2021 · Primary completion Dec 9, 2021
Drug: [14C]-NV-5138 · For: Healthy Volunteers
Sites: Ruddington, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- High-concentration hydrogen mitigates cognitive impairment in a murine model of Sepsis-associated encephalopathy by enhancing oligodendrocyte maturation and myelination in the mPFC.
Yu J, Qi W, Li F, et al. · Prog Neuropsychopharmacol Biol Psychiatry 2026
- Tankyrase-2 regulates adipocyte differentiation through AMPK/mTOR signaling.
Rauch B, Ujlaki G, Poliska S, et al. · FEBS J 2026
- A novel, experimental design to assess rapid antidepressant action: Results from a phase 1b randomized trial of NV-5138.
Targum SD, Sanacora G, Formella AE, et al. · J Psychiatr Res 2026
- Bulky substrates of isoleucine 2-epimerase: α-Neopentylglycine and NV-5138.
Sorbara NT, Black AKA, Bearne SL · Bioorg Med Chem Lett 2025
- Advanced Model-based Approach to Evaluate Human Plasma, Cerebrospinal Fluid, and Neuronal mTORC1 Activation Biomarkers After NV-5138 Administration in Healthy Volunteers.
Nasser A, Randall Owen J, Gomeni R, et al. · Clin Ther 2024
Also in development for Treatment Resistant Depression
- PsilocybinCOMP360Phase 34 trials
COMPASS Pathways · Treatment Resistant Depression, Major Depressive Disorder, Anorexia Nervosa
- PBOPhase 32 trials
SK Life Science, Inc. · Primary Generalized Epilepsy, Treatment Resistant Depression
- NRX-101Phase 31 trial
NeuroRx, Inc. · Treatment Resistant Depression, Treatment Resistant Depression (TRD)
- BPL-003Phase 22 trials
Beckley Psytech Limited · Treatment Resistant Depression
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.